Novartis halts malaria drug trial against COVID19 amid participant shortfall Reuters Discover Thomson ReutersFinancialGovernment SolutionsLegalReuters News AgencyRisk Management SolutionsTax AccountingBlog Answers OnInnovation Thomson ReutersDirectory of sitesLoginContactSupportBusinessMarketsWorldPoliticsTVMoreUnited States Health NewsJune 19 2020 917 PM in 3 daysNovartis halts malaria drug trial against COVID19 amid participant shortfallJohn Miller3 Min ReadZURICH Reuters Swiss drugmaker Novartis NOVNS is halting its trial of malaria drug hydroxychloroquine HCQ against COVID19 after struggling to find participants it said on Friday as data emerged from other studies raising doubts about its efficacyFILE PHOTO A pharmacist displays a box of Hydroxychloroquine at the CHR Centre Hospitalier Regional de la Citadelle Hospital amid the coronavirus disease COVID19 in Liege Belgium June16 2020REUTERSYves HermanFile PhotoNovartis trial began in April and sought to test the drug in 440 hospitalized patientsBut the project only managed to recruit a handfulNovartis move follows this weeks US Food and Drug Administrations FDA decision to revoke emergency use authorization for hydroxychloroquine against COVID19 on grounds it and a related drug chloroquine are unlikely to help patientsHydroxychloroquine also used to treat inflammatory disorders including rheumatoid arthritis and lupus has been caught in a political debate as US President Donald Trump promoted it even though there was no scientific evidence that it helps against the new coronavirusSeveral studies of the decadesold malaria drug including in Britain were recently halted after scientists concluded it was useless against COVID19This week the World Health Organization halted the hydroxychloroquine arm of one of its trialsThe recruitment challenge facing our hydroxychloroquine trial has made it unlikely that the clinical team will be able to collect meaningful data in a reasonable time frame to determine the efficacy of hydroxychloroquine in treating patients with COVID19 Novartis saidTrump who said he used HCQ as a COVID19 prophylactic criticized the FDA decision to revoke its emergency authorizationThe Baselbased company said its study so far raised no safety issues and drew no conclusions about HCQs efficacyNovartis trial coincided with increasing use of Gilead Sciences GILDO drug remdesivir which has been shown in trials to speed recovery from COVID19The FDA has also warned against mixing remdesivir with HCQFrench drugmaker Sanofi SASYPA which previously suspended recruitment of patients for two HCQ trials told Reuters it would make a decision in coming days over whether it would resume its own studiesNovartis had donated up to 130 million doses of hydroxychloroquine including millions in the United States and Chief Executive Vas Narasimhan two months ago pegged it as the companys biggest hope against the new coronavirusReporting by John Miller and Matthias Blamont in Paris Editing by Cynthia OstermanOur StandardsThe Thomson Reuters Trust Principles0 0narrowbrowserandphonemediumbrowserandportraittabletlandscapetabletmediumwidebrowserwidebrowserandlargermediumbrowserandlandscapetabletmediumwidebrowserandlargerabovephoneportraittabletandaboveaboveportraittabletlandscapetabletandabovelandscapetabletandmediumwidebrowserportraittabletandbelowlandscapetabletandbelowAppsNewslettersAdvertise with UsAdvertising GuidelinesCookiesTerms of UsePrivacyAll quotes delayed a minimum of 15 minutesSee here for a complete list of exchanges and delays 2020 ReutersAll Rights Reserved